These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18709483)

  • 1. Long-term effects of lipase inhibition by orlistat on gastric emptying and orocecal transit time of a solid meal.
    Kocełak P; Zahorska-Markiewicz B; Jonderko K; Olszanecka-Glinianowicz M; Zak-Gołab A; Holecki M; Kamińska M; Szymszal M
    J Gastroenterol; 2008; 43(8):609-17. PubMed ID: 18709483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influences of fat restriction and lipase inhibition on gastric emptying in obesity.
    Mathus-Vliegen EM; van Ierland-van Leeuwen ML; Bennink RJ
    Int J Obes (Lond); 2006 Aug; 30(8):1203-10. PubMed ID: 16462818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects.
    Drent ML; Popp-Snijders C; Adèr HJ; Jansen JB; van der Veen EA
    Obes Res; 1995 Nov; 3(6):573-81. PubMed ID: 8653534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity.
    Mathus-Vliegen EM; Van Ierland-Van Leeuwen ML; Terpstra A
    Aliment Pharmacol Ther; 2004 Mar; 19(5):601-11. PubMed ID: 14987329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
    Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ
    Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
    Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.
    Enç FY; Ones T; Akin HL; Dede F; Turoğlu HT; Ulfer G; Bekiroğlu N; Haklar G; Rehfeld JF; Holst JJ; Ulusoy NB; Imeryüz N
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G482-9. PubMed ID: 19109408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine.
    Sternby B; Hartmann D; Borgström B; Nilsson A
    Clin Nutr; 2002 Oct; 21(5):395-402. PubMed ID: 12381337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.
    Carrière F; Renou C; Ransac S; Lopez V; De Caro J; Ferrato F; De Caro A; Fleury A; Sanwald-Ducray P; Lengsfeld H; Beglinger C; Hadvary P; Verger R; Laugier R
    Am J Physiol Gastrointest Liver Physiol; 2001 Jul; 281(1):G16-28. PubMed ID: 11408251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
    Ellrichmann M; Kapelle M; Ritter PR; Holst JJ; Herzig KH; Schmidt WE; Schmitz F; Meier JJ
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3995-8. PubMed ID: 18647814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
    Sjostrom L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar H; Krempf M;
    Ter Arkh; 2000; 72(8):50-4. PubMed ID: 11019429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor.
    Borovicka J; Schwizer W; Guttmann G; Hartmann D; Kosinski M; Wastiel C; Bischof-Delaloye A; Fried M
    Gut; 2000 Jun; 46(6):774-81. PubMed ID: 10807887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous non-invasive measurement of liquid gastric emptying and small bowel transit by combined 13C-acetate and H2-lactulose breath test.
    Bertram F; Andresen V; Layer P; Keller J
    J Breath Res; 2014 Nov; 8(4):046007. PubMed ID: 25417651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal.
    Ellrichmann M; Ritter PR; Otte JM; Schrader H; Banasch M; Brunke G; Herzig KH; Seebeck J; Schmidt WE; Schmitz F
    Regul Pept; 2007 Mar; 139(1-3):136-40. PubMed ID: 17175037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes.
    O'Donovan D; Horowitz M; Russo A; Feinle-Bisset C; Murolo N; Gentilcore D; Wishart JM; Morris HA; Jones KL
    Diabetologia; 2004 Dec; 47(12):2208-14. PubMed ID: 15662558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.